Tizhi Wu

State Key Laboratory Of Natural Medicines, Jiangsu Key Laboratory Of Drug Design And Optimization
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Journal: Future medicinal chemistry

Published: March 12, 2026

Selective Targeting of STAT6: Recent Advances and Future Perspectives.

Selective Targeting of STAT6: Recent Advances and Future Perspectives.

Journal: Medicinal research reviews

Published: January 18, 2026

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Journal: European journal of medicinal chemistry

Published: October 01, 2025

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Journal: ACS medicinal chemistry letters

Published: September 27, 2025

Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors.

Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 15, 2025

Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis.

Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis.

Journal: Journal of medicinal chemistry

Published: April 16, 2025

Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting.

Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting.

Journal: Journal of medicinal chemistry

Published: February 13, 2025

Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.

Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.

Journal: Journal of medicinal chemistry

Published: October 23, 2023

Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.

Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.

Journal: European journal of medicinal chemistry

Published: June 29, 2023

Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.

Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.

Journal: European journal of medicinal chemistry

Published: June 12, 2023

A patent review of selective CDK9 inhibitors in treating cancer.

A patent review of selective CDK9 inhibitors in treating cancer.

Journal: Expert opinion on therapeutic patents

Published: May 02, 2023

Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

Journal: Journal of medicinal chemistry

Published: September 01, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026